Nasdaq
$1.73▼ 0.57%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $74.0MShares out 42.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.7After-hours26.10.08 06:024Ownership#●●●#●●●
Acrivon Therapeutics, Inc.
Insider Mary Miller of Acrivon Therapeutics reported a change in beneficial ownership of securities as of October 5, 2026. This filing serves as a standard disclosure regarding insider equity transactions.…more
$1.73-0.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:304Ownership
Acrivon Therapeutics, Inc.
Insider Michaela Levin of Acrivon Therapeutics reported a change in share ownership effective August 31, 2026. This filing serves as a standard disclosure of insider equity transactions via Form 4.…more
$1.73-0.57%vs prev closeView filingShare - 9.2After-hours26.09.03 05:263Ownership
Acrivon Therapeutics, Inc.
An executive or major shareholder of Acrivon Therapeutics has filed a Power of Attorney, authorizing company representatives to handle SEC reporting requirements. This grants the designated attorneys-in-fact the authority to prepare and submit mandatory filings such as Forms 3, 4, 5, and Form 144 on behalf of Michaela Levin.…more
$1.73-0.57%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:30#●●●#●●●#●●●
Acrivon Advances ACR-7280 CDK11 Inhibitor Toward 2027 IND Filing
Acrivon Therapeutics is advancing its oral CDK11 inhibitor, ACR-7280, with plans to submit an IND application in the first half of 2027. While the candidate showed tumor regression in preclinical AML models, it remains in the early stages of development.…more
$1.73-0.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2Pre-market26.09.02 21:00
●●●●●●●● ●●●●● ●●●●●●
Acrivon Therapeutics announced that its CEO will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. This is a routine investor relations event and does not contain new material financial information.…more
$1.73-0.57%vs prev close - 8.31Pre-market26.08.31 21:30
●●●●●●●● ●●●●● ●●●●●●
Acrivon Therapeutics has appointed biotechnology veteran Dr. Michaela Levin as its new Chief Business Officer. The company aims to leverage her expertise to drive strategic partnerships and maximize the value of its proprietary AI-driven AP3 platform.…more
$1.73-0.57%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report